Fighting against nervous system disorders has been the main mission of Cassava Sciences (NASDAQ: SAVA) that spends millions to develop a viable drug to treat, for example, Alzheimer’s disease. From $3.14 to $8.12 SAVA instantly jumps in premarket on 17 million shares amid announcing final results of a phase 2b clinical study of Sumifilam in patients with Alzheimer’s illness.
Even though the EPS is -0.2130 and the stock’s dramatic fall on May 15 long term traders will most likely buy SAVA shares in millions by hope in the next results of the current study. No one is safe from Alzheimer’s disease; even rich and poor. Therefore, many investors are gathering around this issue to come out with an optimal solution.
$7 or $8 shares are not as expensive as Amazon’s or Berkshire Hataway’s. Getting SAVA shares could finally solve the unsolved problem of Alzheimer’s disease forever. Flu and other viruses became curable, why not finish the diseases of the elderly.
Editor and Computer Expert
A hardcore tech enthusiast and computer expert Uson Abdilazhanov who holds a degree in communications started writing in his personal blogs since 2012. That time he was interested in the technical part of the computer. But now the software aspect plays an important role in his career. Currently, he runs a PC building and repairing shop which helps a lot of designers and gamers who always like to try new things.